Today in News History
On July 12, several notable moments in the history of News stand out. In 154, Bardaisan, Syrian astrologer, scholar, and philosopher (died 222) was born. In 1302, Robert II, Count of Artois (born 1250) passed away. In 1302, Battle of the Golden Spurs (Guldensporenslag in Dutch): A coalition around the Flemish cities defeats the king of France's royal army. In 1302, Pierre Flotte, French politician and lawyer passed away. In 1603, Kenelm Digby, English astrologer, courtier, and diplomat (died 1665) was born. In 1723, Jean-François Marmontel, French historian and author (died 1799) was born. In 1826, Alexander Afanasyev, Russian ethnographer and author (died 1871) was born. In 1881, Isabel Martin Lewis, American astronomer and author (died 1966) was born. In 1909, Jacques Clemens, Dutch catholic priest (died 2018) was born. In 1950, J. R. Morgan, Welsh author and academic was born. Together, these milestones provide historical context for today's news news and ongoing narratives.
Lancet paper critique – Part 3
Finally, you may think, some figures. In this blog I want to look at some of the figures on adverse effects seen in a number of statin trials – such figures as it is possibly to unearth anyway. Unlike the CTT in Oxford I – along with almost every other researcher in the world – []
Narrative Intelligence Brief
This article was published by Dr. Malcolm Kendrick, a source frequently categorized with a center bias based in United Kingdom. Our narrative intelligence engine continuously monitors coverage from this outlet to track framing, bias, and rhetorical patterns. Our initial algorithmic scan of this specific piece did not flag high-confidence rhetorical techniques, suggesting a generally straightforward reporting style or neutral framing. By understanding the editorial perspective of Dr. Malcolm Kendrick, readers can better contextualize the information presented and compare it across our broader media matrix to find the real narrative.
More from Dr. Malcolm Kendrick
Analysis Methodology
This narrative analysis was generated using the CoDataLab Global Intelligence Engine. Our proprietary AI scans thousands of cross-border sources to identify sentiment patterns, framing techniques, and potential media bias. While AI provides the data-driven foundation, our objective is to empower readers with additional context beyond the standard headline.The content displayed above is a structured summary designed for rapid information processing. For the full original report, please visit the source outlet.More Coverage
Discussion
"alexander zverev"
How other outlets are covering this story
Compare narratives across 6 related reports from 6 sources. Real Narrative News aggregates the coverage spectrum so you can see who emphasises what — bias tags reflect the outlet, not the story.
Coverage bias distribution
6 sources
Left 0%
Center 33%
Right 67%
Brown Eyed Baker
· Mar 13, 2026
Friday Things #588
Friday Things 588 1. Thank you for the enormous amount of prayers and well wishes as Dominic went into his scan last week. While he is not yet back in full remission, the scan showed continued improvement in both the number of sites and uptake intensity, with no new spots or progression. We are grateful that things continue [] READ: Friday Things 588
mindbodygreen
· Jun 26, 2026
This 4-Minute Strength Routine Improved Key Markers Of Healthy Aging
Proof that every minute counts
NaturalNews.com
· Jun 23, 2026
New Study Links Strength Training to Lower Dementia Risk, Longer Life
(NaturalNews) A new study published in the British Journal of Sports Medicine has linked regular strength training to a lower risk of dementia and longer life. Rese...
Seeking Alpha
· Jun 23, 2026
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation - Slideshow
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation - Slideshow
The Standard
· Jul 1, 2026
Experience the Lancôme Longevity Clinic at Selfridges this July
Discover this pioneering residency, which explores the benefits of a pro-longevity lifestyle as well as Lancôme’s game-changing new product range
Chris Kresser
· Apr 21, 2026
RHR: The GLP-1 Blind Spot: What Ozempic Won’t Do for Your Metabolic Health
In this episode of Revolution Health Radio, Chris explores the science behind GLP-1 medications, including their powerful effects on appetite, weight loss, and cardiometabolic risk. He also uncovers the critical blind spots in the current conversation, including new research on long-term side effects, nutrient deficiencies, muscle loss, and the high rate of weight regain after discontinuation. You’ll learn why these drugs may be effective in the short term but fall short of addressing the root causes of obesity and metabolic dysfunction. Chris also explains who may benefit most from GLP-1 therapy and how to use these medications as part of a comprehensive strategy that includes nutrition, resistance training, and lifestyle interventions. The post RHR: The GLP-1 Blind Spot: What Ozempic Won’t Do for Your Metabolic Health appeared first on Chris Kresser.
Topics:
Related coverage for "Lancet paper critique – Part 3": Brown Eyed Baker — Friday Things #588. mindbodygreen — This 4-Minute Strength Routine Improved Key Markers Of Healthy Aging. NaturalNews.com — New Study Links Strength Training to Lower Dementia Risk, Longer Life. Seeking Alpha — Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation - Slideshow. The Standard — Experience the Lancôme Longevity Clinic at Selfridges this July. Chris Kresser — RHR: The GLP-1 Blind Spot: What Ozempic Won’t Do for Your Metabolic Health